Glaukos Corporation (GKOS)
NYSE: GKOS · Real-Time Price · USD
88.40
-1.63 (-1.81%)
Nov 17, 2025, 4:00 PM EST - Market closed
Glaukos Revenue
Glaukos had revenue of $133.54M in the quarter ending September 30, 2025, with 38.14% growth. This brings the company's revenue in the last twelve months to $469.82M, up 30.38% year-over-year. In the year 2024, Glaukos had annual revenue of $383.48M with 21.85% growth.
Revenue (ttm)
$469.82M
Revenue Growth
+30.38%
P/S Ratio
10.67
Revenue / Employee
$472,181
Employees
995
Market Cap
5.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 383.48M | 68.77M | 21.85% |
| Dec 31, 2023 | 314.71M | 31.85M | 11.26% |
| Dec 31, 2022 | 282.86M | -11.15M | -3.79% |
| Dec 31, 2021 | 294.01M | 69.05M | 30.70% |
| Dec 31, 2020 | 224.96M | -12.03M | -5.07% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
GKOS News
- 6 days ago - Glaukos Corporation (GKOS) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 14 days ago - Glaukos Announces Participation in Upcoming Investor Conferences - Business Wire
- 19 days ago - Glaukos Corporation (GKOS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - Glaukos Announces Third Quarter 2025 Financial Results - Business Wire
- 4 weeks ago - US FDA approves Glaukos' new eye therapy - Reuters
- 4 weeks ago - Glaukos Announces FDA Approval of Epioxa™ - Business Wire
- 4 weeks ago - Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting - Business Wire
- 5 weeks ago - Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29 - Business Wire